Before starting any IL-2 and targeted therapy treatments, the patient had an abnormal NK cell function of 4.56%, which then increased in response to treatment and abnormal CLL cells decreased. The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.